Quick Answer
ADC Therapeutics SA reported Total Revenue of $81.36 million for fiscal year 2025.
ADC Therapeutics SA — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $81.36M +14.9% |
$70.84M +1.8% |
$69.56M -66.9% |
$209.91M | — | — |
| Revenue (ASC 606) | — | — | $69.06M -7.8% |
$74.91M | — | — |
| Net Income | -$142.62M +9.6% |
-$157.85M +34.2% |
-$240.05M -52.8% |
-$157.13M | — | — |
| Diluted EPS | -$1.12 +30.9% |
-$1.62 +44.9% |
-$2.94 -46.3% |
-$2.01 | — | — |
| Total Assets | $323.15M +0.4% |
$321.98M -9.2% |
$354.78M -27.7% |
$490.86M -20.6% |
$617.97M +20.3% |
$513.69M +273.1% |
| Cash and Equivalents | $261.34M +4.2% |
$250.87M -10.0% |
$278.60M -14.7% |
$326.44M | — | — |
| Stockholders Equity | -$185.83M +8.3% |
-$202.64M -36.7% |
-$148.25M -286.6% |
$79.45M -48.4% |
$154.03M | — |
| R&D Expense | $104.00M -5.1% |
$109.63M -13.8% |
$127.13M -31.8% |
$186.46M +18.0% |
$158.00M +11.2% |
$142.03M +32.1% |
| Operating Income | -$121.50M +7.0% |
-$130.65M +21.3% |
-$165.99M -34.6% |
-$123.34M | — | — |
| Shares Outstanding | 125.75M +27.2% |
98.86M +20.1% |
82.29M +2.0% |
80.64M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $16.43M | -11.0% | -12.8% |
| Revenue (ASC 606) | September 30, 2025 | $15.75M | -12.6% | -12.9% |
| Net Income | September 30, 2025 | -$40.97M | +6.8% | +27.7% |
| Diluted EPS | September 30, 2025 | -$0.30 | +28.6% | +40.0% |
| Total Assets | September 30, 2025 | $289.76M | -17.0% | -9.9% |
| Cash and Equivalents | September 30, 2025 | $234.74M | -14.4% | -11.3% |
| Stockholders Equity | September 30, 2025 | -$238.18M | -38.5% | -19.6% |
| R&D Expense | September 30, 2025 | $26.80M | -17.5% | -10.9% |
| Operating Income | September 30, 2025 | -$30.97M | +12.9% | +29.9% |
| Shares Outstanding | September 30, 2025 | 112.63M | +16.5% | +0.1% |
- ADC Therapeutics SA reported Total Revenue of $81.36 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +14.9% in Total Revenue compared to the prior fiscal year.
- ADC Therapeutics SA reported Revenue (ASC 606) of $69.06 million for fiscal year 2023.
- ADC Therapeutics SA showed a decrease of -7.8% in Revenue (ASC 606) compared to the prior fiscal year.
- ADC Therapeutics SA reported Net Income of -$142.62 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +9.6% in Net Income compared to the prior fiscal year.
- ADC Therapeutics SA reported Diluted EPS of $1.12 per share (loss) for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +30.9% in Diluted EPS compared to the prior fiscal year.
- ADC Therapeutics SA reported Total Assets of $323.15 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +0.4% in Total Assets compared to the prior fiscal year.
- ADC Therapeutics SA reported Cash and Equivalents of $261.34 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +4.2% in Cash and Equivalents compared to the prior fiscal year.
- ADC Therapeutics SA reported Stockholders Equity of -$185.83 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +8.3% in Stockholders Equity compared to the prior fiscal year.
- ADC Therapeutics SA reported R&D Expense of $104.00 million for fiscal year 2025.
- ADC Therapeutics SA showed a decrease of -5.1% in R&D Expense compared to the prior fiscal year.
- ADC Therapeutics SA reported Operating Income of -$121.50 million for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +7.0% in Operating Income compared to the prior fiscal year.
- ADC Therapeutics SA reported Shares Outstanding of 125.75 million shares for fiscal year 2025.
- ADC Therapeutics SA showed an increase of +27.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: